Patrick R. Thompson
Great. Thanks, Steve. I'll start by walking through the key drivers of our Q2 results. Transaction value was $481 million, up 49% year- over-year, driven by 71% year-over-year growth in our P&C vertical. In our health vertical, transaction value declined 32% year-over- year, coming in slightly below our expectations. Adjusted EBITDA for the quarter was $24.5 million, increasing 31% year-over-year. This slightly lagged our expectations due to a modestly lower take rate in the quarter, driven by our decision to accelerate our strategy to scale back parts of our higher-margin under-65 business, along with some nice incremental partner wins in P&C that are at lower- than-average take rates. For the quarter, adjusted EBITDA represented 62% of contribution, up from 56% in the prior year. Adjusted EBITDA included $35.3 million of add-backs related to the FTC matter, consisting of $2.3 million of legal expenses and an additional $33 million reserve recorded to reflect the total $45 million settlement payable. Looking ahead, we expect record third quarter transaction value as we benefit from continued strong demand from the largest carriers in our marketplace. Accordingly, we expect P&C transaction value to grow approximately 35% year-over-year. In our health vertical, we expect transaction value to decline approximately 40% to 45% year-over-year, reflecting a decrease in our under-65 business from Q2 levels as well as continued challenging conditions in Medicare Advantage. For under-65 specifically, we expect Q3 transaction value of approximately $18 million, reflecting a 54% year-over-year decline and contribution of about $1 million, a roughly 80% decline year-over-year. To provide greater transparency into the new baseline for our health vertical, this quarter's earnings materials include transaction value and contribution for our under-65 business over the past 6 quarters. We expect 2025 under-65 transaction value of $95 million to $100 million and contribution of about $10 million, resulting in a take rate of about 10% at the midpoint. By comparison, 2024 transaction value contribution and take rate were $179 million, $29 million and 16%, respectively. Looking ahead, we expect that under-65 will generate annual contribution in the single-digit millions, reflecting the reset in both scale and profitability for this subvertical. Moving to our consolidated financial guidance. We expect Q3 transaction value to be between $545 million and $570 million, representing a year-over-year increase of 23% at the midpoint. We expect revenue to be between $270 million and $290 million, representing a year-over-year increase of 8% at the midpoint. Adjusted EBITDA is expected to be between $25.5 million and $27.5 million, representing a year-over-year increase of 1% at the midpoint, including a $4 million impact from an expected year-over- year decline in under-65 contribution. We expect overhead to increase sequentially by approximately $1 million as we continue to selectively invest in headcount to support and drive growth. We generated significant cash flow and made solid progress in deleveraging our balance sheet during the quarter. In Q2, we generated $22 million of cash and ended the quarter with $85 million of cash and a net debt to adjusted EBITDA ratio of 0.6x. Excluding nonrecurring payments related to the FTC matter, with $33.5 million expected to be paid in Q3 and the remaining $11.5 million in Q4, we expect to convert a significant portion of adjusted EBITDA into unlevered free cash flow, providing us with substantial financial flexibility going forward. Finally, I'm pleased to announce that on August 4, we extended the maturity of $142.6 million of the $156.3 million of indebtedness outstanding under our credit facilities by 1 year through July of 2027. The remaining $14 million will mature in July of 2026. With that, operator, we are ready to take the first question.